Management of Patients with Hemangiopericytoma: Case Report and Literature Review
American Journal of Health Research
Volume 7, Issue 2, March 2019, Pages: 24-30
Received: May 9, 2019; Accepted: Jul. 3, 2019; Published: Jul. 24, 2019
Views 150      Downloads 20
Authors
Bruno Barreira Cardoso, Universidade Potiguar, Natal, Brazil
Daniely Pessoa Moreira, Universidade Potiguar, Natal, Brazil
Francisco de Assis Fernandes Tavares, Universidade Potiguar, Natal, Brazil
Luiz Frederico Bezerra Honorato Junior, Universidade Potiguar, Natal, Brazil
Nicole Cindy Fonseca Santos, Universidade Potiguar, Natal, Brazil
Rebecca Renata Lapenda do Monte, Universidade Potiguar, Natal, Brazil
Renan Cavalcante Souza, Universidade Potiguar, Natal, Brazil
Renata Carneiro Melo, Universidade Potiguar, Natal, Brazil
Luciana de Aguiar Correa, Pediatrics Department, Hospital Infantil Varela Santiago, Natal, Brazil
Renato Serquiz Elias Pinheiro, Neurology Department, Universidade Potiguar, Natal, Brazil
Article Tools
Follow on us
Abstract
The hemangiopericytomas (HPCs) are rare tumors of the dural base and correspond of less than 1% of all primary Central Nervous System (CNS) tumors. It usually affects adult males with 40 to 50 years old and has a supratentorial location (70%), followed by posterior fossa (15%) and spine (15%). Generally, it has fast progression and manifests clinically through headache, focal neurological deficits and epileptic seizures. The tumor has high incidence of local recurrence, from 34% to 90%, and it is estimated that the follow-up of these patients should be done for at least 7, 5 years. The percentage of long-distance metastases is lower, 12% to 55%, affecting especially bones, lungs and liver, in decreasing order. The objective of this study is to evaluate the contradictions when approaching these tumors and to analyze a rare case of pediatric involvement. It was prepared a case report and a literature review was made using the data bases MEDLINE®, PubMed and Cochrane, where 31 relevant articles were selected related to the proposed study. The outcome of HPC treatment can change according to the tumor’s location in the CNS or extracranial, the tumor’s size and the histopathological classification. Therefore, many studies have been proposed observing the answer of the surgical resection, the adjuvant radiotherapy, the radiosurgery and the antiangiogenic therapies.
Keywords
Hemangioperycitoma, Radiosurgery, Radiotherapy, Surgery
To cite this article
Bruno Barreira Cardoso, Daniely Pessoa Moreira, Francisco de Assis Fernandes Tavares, Luiz Frederico Bezerra Honorato Junior, Nicole Cindy Fonseca Santos, Rebecca Renata Lapenda do Monte, Renan Cavalcante Souza, Renata Carneiro Melo, Luciana de Aguiar Correa, Renato Serquiz Elias Pinheiro, Management of Patients with Hemangiopericytoma: Case Report and Literature Review, American Journal of Health Research. Vol. 7, No. 2, 2019, pp. 24-30. doi: 10.11648/j.ajhr.20190702.12
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Chheda MG, Wen PY. Uncommon brain tumors. In: Eichler AF, Loeffler JS, editors. UpToDate. [Internet]. Waltman (MA): UpToDate Inc. 2019. [uptodate 2019 Feb 15; cited May 2019]. [51 screens] Available from: https://www.uptodate.com/contents/uncommon-brain-tumors?source=history_widget.
[2]
Hayenga HN, Bishop AJ, Wardak Z, Sen C, Mickey B. Intraspinal Dissemination and Local Recurrence of an Intracranial Hemangiopericytoma. World neurosurgery. 2019; 123: 68-75.
[3]
Demicco EG, Meyer C. Solitary fibrous tumor. In: Maki R, DeLaney TF, R JJ, Friedberg JS, Berman RS, Pollock RE, Shah S, Collins SA, editors. [UpToDate]. Waltham (MA). UpToDate Inc; 2019. [updated 2019 Mar 22; cited 2019 May]; [39 screens]. Available from: https://www.uptodate.com/contents/solitary-fibrous-tumor?source=history_widget.
[4]
Jeon SH, Park SH, Kim JW, Park CK, Paek SH, Kim IH. Efficacy of adjuvant radiotherapy in the intracranial hemangiopericytoma. Journal of Neuro-Oncology. 2018: 137 (3); 567–573.
[5]
Roth J, Constantini S. 5ALA in pediatric brain tumors is not routinely beneficial. Child's Nervous System. 2017; 33 (5): 787-792.
[6]
Lee, C.-K., Liu, K.-L., & Huang, S.-K. (2019). A dedifferentiated solitary fibrous tumor of the parotid gland: a case report with Cytopathologic findings and review of the literature. Diagnostic Pathology, 14 (1).
[7]
Li YQ, Chua ET, Chua KL, Chua ML. “Cor Occidere”: a novel strategy of targeting the tumor core by radiosurgery in a radio- and chemo-resistant intracranial hemangiopericytoma. Chin Clin Oncol 2018; 7 (1): 10.
[8]
Semerci YS., Demirel G, Vatansever B, Gundogdu S, Bolukbasi F, Oran G et al. Urgent surgical management of congenital intracranial hemangiopericytoma in a preterm neonate. British Journal of Neurosurgery. 2017; 1–3.
[9]
Koc AM, Oner AY, Ucar M, Bor AO. Intracranial Hemangiopericytoma in a Child: A Case Report with Magnetic Resonance Spectroscopy Findings. Turk Neurosurg 2016; 26 (1): 173-175.
[10]
Melone AG, D’Elia A, Santoro F, Salvati M, Delfini R, Cantore G et al. Intracranial Hemangiopericytoma—Our Experience in 30 Years: A Series of 43 Cases and Review of the Literature. World Neurosurgery. 2014; 81 (3-4): 556–562.
[11]
Bridges K, Sauerwein R, Grafe MR, Tsikitis V. (Liana), Halfpenny A, Raslan AM. Seeding of Abdomen with Primary Intracranial Hemangiopericytoma by Ventriculoperitoneal Shunt: Case Report. World Neurosurgery. 2017; 10: 1048.e7–1048.e14.
[12]
Sweid A, Noureldine MHA, Nasser S, Badra M, Saikali I. A Case Report of Meningeal Hemangiopericytoma: A 9-Year Journey from the Brain to the Spine. World neurosurgery. 2019; 122: 459-463.
[13]
Wang W, Zhang GJ, Zhang LW, Li D, Wu Z, Zhang J-T. Long-Term Outcome and Prognostic Factors After Repeated Surgeries for Intracranial Hemangiopericytomas. World Neurosurgery. 2017; 107: 495–505.
[14]
Campobasso D, Ferretti S, Pilato FP, Frattini A. Giant bilateral renal metastases from a meningeal hemangiopericytoma. Journal of cancer research and therapeutics. 2018; 14 (6): 1434.
[15]
Towner JE, Johnson MD, Li YM. Intraventricular Hemangiopericytoma: A Case Report and Literature Review. World Neurosurgery. 2016; 89: 728.e5–728.e10.
[16]
Koc AM, One AY, Ucar M, Borcek AO. Intracranial Hemangiopericytoma in a Child: A Case Report with Magnetic Resonance Spectroscopy Findings. Turkish neurosurgery. 2016; 26 (1): 173-175.
[17]
Chen L, Yang Y, Yu X, Gui Q, Xu B, Zhou D. Multimodal treatment and management strategies for intracranial hemangiopericytoma. Journal of Clinical Neuroscience. 2015; 22 (4): 718-725.
[18]
Ma L, Wang L, Fang X, Zhao CH, Sun L. Diagnosis and treatment of solitary fibrous tumor/hemangiopericytoma of central nervous system. Retrospective report of 17 patients and literature review. Neuroendocrinology Letters. 2017; 39 (2).
[19]
Zhang G-J, Wu Z, Zhang L-W, Li D, Zhang J-T. Surgical Management and Adverse Factors for Recurrence and Long-Term Survival in Patients with Hemangiopericytoma. World Neurosurgery. 2017; 104: 95–103.
[20]
Lee EJ, Kim JH, Park ES, Khang SK, Cho YH, Hong SH et al. The impact of postoperative radiation therapy on patterns of failure and survival improvement in patients with intracranial hemangiopericytoma. Journal of Neuro-Oncology. 2015; 127 (1): 181–190.
[21]
Sweid A, Noureldine MHA, Nasser S, Badra M, Saikali I. A Case Report of Meningeal Hemangiopericytoma: A 9-Year Journey from the Brain to the Spine. World neurosurgery. 2019; 122: 459-463.
[22]
Trifiletti DM, Mehth, GU, Grover S, Sheehan JP. Clinical management and survival of patients with central nervous system hemangiopericytoma in the National Cancer Database. Journal of Clinical Neuroscience. 2017; 44: 169-174.
[23]
Choi J, Park S-H, Khang SK, Suh Y-L, Kim SP, Lee YS et al. Hemangiopericytomas in the Central Nervous System: A Multicenter Study of Korean Cases with Validation of the Usage of STAT6 Immunohistochemistry for Diagnosis of Disease. Annals of Surgical Oncology; 2016; 23 (S5): 954–96.
[24]
Kamamoto D, Ohara K, Kitamura Y, Yoshida K, Kawakami Y, Sasaki H. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. Journal of neuro-oncology. 2018; 139 (2): 251-259.
[25]
Spina A, Boari N, Gagliardi F, Donofrio CA, Franzin A, Mortini P. The current role of Gamma Knife radiosurgery in the management of intracranial haemangiopericytoma. Acta Neurochirurgica. 2016; 158 (4): 635–642.
[26]
Kim BS, Kong DS, Seol HJ, Nam DH, Lee J I. Gamma knife radiosurgery for residual or recurrent intracranial hemangiopericytomas. Journal of Clinical Neuroscience. 2017; 35: 35-41.
[27]
Shaigany K, Fang CH, Patel TD, Parque RC, Baredes S, Eloy JA. Shaigany, A population-based analysis of Head and Neck hemangiopericytoma. The Laryngoscope. 2015; 126 (3): 643-650.
[28]
Jong I, Chen S, Leung YL, Cheung SK, Ho C. 11C-Acetate PET/CT in a Case of Recurrent Hemangiopericytoma. Clinical Nuclear Medicine. 2014; 39 (5): 478–479.
[29]
Iampreechakul P, Tirakotai W, Lertbutsayanukul P, Siriwimonmas S, & Liengudom A. Pre-operative Embolization of Intracranial and Extracranial Tumozrs: A Review of 37 Cases. Journal of the Medical Association of Thailand= Chotmaihet thangphaet. 2016; 99: S91-119.
[30]
Wang X, Zhang X, Zhou Q, Zhou X, Chen L, Huang G, et al. Hemangiopericytoma Arose From the Site of Meningioma Resection. The Journal of craniofacial surgery. 2017; 28 (4): e329-e330.
[31]
Tata A, Cohen-Inbar, Sheehan JP. Treatment of orbital solitary fibrous tumour with gamma knife radiosurgery and systematic review of literature. Case Reports, 2016, bcr2016217114.
[32]
Lee CK, Liu KL, Huang SK. A dedifferentiated solitary fibrous tumor of the parotid gland: a case report with Cytopathologic findings and review of the literature. Diagnostic Pathology; 2019; 14 (1).
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186